Drug Trial Radar · NCT00642902
A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS)
Last checked: Nov 20, 2026Latest source record: May 24, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
255
Actual
Start
Apr 2008
Primary completion
Sep 2009
Study completion Sep 2009
Sponsor
- Lead sponsor
- EMD SeronoIndustry
- Sponsor type
- Industry
- First posted
- Mar 25, 2008
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the safety and tolerability of atacicept and to explore if atacicept reduces central nervous system inflammation in subjects with relapsing multiple sclerosis (RMS) as assessed by frequent magnetic resonance imaging (MRI). This study is randomised. Study medication is administered via subcutaneous (under the skin) injections.
Conditions
- Relapsing Multiple Sclerosis
Interventions
AtaciceptDrug
Atacicept will be administered subcutaneously at a dose of 25 milligram (mg) twice a week for initial 4 weeks as loading dose, followed by 25 mg once a week for subsequent 32 weeks.
AtaciceptDrug
Atacicept will be administered subcutaneously at a dose of 75 mg twice a week for initial 4 weeks as loading dose, followed by 75 mg once a week for subsequent 32 weeks.
AtaciceptDrug
Atacicept will be administered subcutaneously at a dose of 150 mg twice a week for initial 4 weeks as loading dose, followed by 150 mg once a week for subsequent 32 weeks.
Placebo matched to ataciceptDrug
Placebo matched to atacicept will be administered subcutaneously twice a week for initial 4 weeks, followed by once a week for subsequent 32 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Number of Time Constant 1 (T1) Gadolinium (Gd)-Enhancing Lesions Per Participant Per ScanTime frame: Weeks 12 to 36
Locations
50 sites in 17 countries. Site status is shown where the registry gives one.
Research Site
Phoenix, Arizona
Research Site
Atlanta, Georgia
Research Site
Northbrook, Illinois
Research Site
East Lansing, Michigan
Research Site
Jefferson, New Hampshire
Research Site
Cleveland, Ohio
Site not named
Philadelphia, Pennsylvania
Research Site
Nashville, Tennessee
Research Site
Box Hill, Australia
Research Site
Fitzroy, Australia
Research Site
New Lambton, Australia
Research Site
Woodville, Australia
Research Site
Innsbruck, Austria
Research Site
Diepenbeek, Belgium
Research Site
Sijsele, Belgium
Research Site
Ontario, Canada
Research Site
Calgary, Alberta, Canada
Research Site
Ottawa, Ontario, Canada
Research Site
Brno, Czechia
Research Site
Hradec Králové, Czechia
Research Site
Olomouc, Czechia
Research Site
Caen, France
Research Site
Saint-Herblain, France
Research Site
Bochum, Germany
Research Site
Düsseldorf, Germany
Research Site
Beirut, Lebanon
Research Site
Kaunas, Lithuania
Research Site
Breda, Netherlands
Research Site
Nieuwegein, Netherlands
Research Site
Rotterdam, Netherlands
Research Site
Dnipropetrovsk, Russia
Research Site
Moscow, Russia
Research Site
Novosibirsk, Russia
Research Site
Saint Petersburg, Russia
Research Site
Samara, Russia
Research Site
Vladimir, Russia
Research Site
Yaroslavl, Russia
Research Site
Yekaterinburg, Russia
Research Site
Barcelona, Spain
Research Site
Madrid, Spain
Showing 40 of 50 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.